In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...

Pembrolizumab in early triple-negative breast cancer shows irAEs similar to KEYNOTE-522, with endocrinopathies and severe gastrointestinal effects being prevalent. The study involved a diverse patient ...

Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials The US Food and Drug Administration (FDA) on Thursday released an alert and summary of findings from two halted ...

Moderna and Merck's experimental cancer vaccine, used in combination with Merck's Keytruda, reduced the risk of the most deadly form of skin cancer spreading to other parts of the body in a clinical ...

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...